Theoretical investigation of aspirin dosage regimen to exhibit optimal antiplatelet effects and decrease risk of upper gastrointestinal lesions
- PMID: 23047244
- DOI: 10.1248/bpb.b12-00030
Theoretical investigation of aspirin dosage regimen to exhibit optimal antiplatelet effects and decrease risk of upper gastrointestinal lesions
Abstract
We investigated dosage regimens for aspirin therapy in regard to antiplatelet effects in patients without gastrointestinal lesions. Findings for inhibition of biosynthesis of thromboxane B(2) (TXB(2)) and prostaglandin E(2) (PGE(2)) were simulated based on pharmacokinetic and pharmacodynamic models using an irreversible process of inhibition of cyclooxygenase-1 (COX-1) by aspirin. We found that the inhibition of biosynthesis of TXB(2) at a steady state was greater than 90% when the dose of aspirin administered exceeded 81 mg, which was considered to exhibit a sufficient antiplatelet effect. Furthermore, it was confirmed that a dose of 162 mg or more is needed to exert an immediate antiplatelet effect on the initial day of administration. On the other hand, the inhibition of biosynthesis of PGE(2) ranged from 40-90% when aspirin was administered at a dose of 10.125-324 mg. Thus, the risk of gastrointestinal lesions differed in a dosage-dependent manner. The biosynthesis inhibition of PGE(2) was calculated to be 37.9%, with that value set as the target level for prevention of gastrointestinal disorders. We also noted a difference between platelets and gastric mucosa cells in regard to the turnover rate of COX-1, and attempted to simulate the inhibition of biosynthesis of TXB(2) and PGE(2) following administration of aspirin. However, it was not possible, as the inhibition of biosynthesis of TXB(2) was greater than 90% and that of PGE(2) was less than 37.9%, even with various dosage regimens. Our findings suggest that it is difficult to determine a rational dosage regimen of aspirin to exert an antiplatelet effect without inducing gastrointestinal lesions.
Similar articles
-
Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin.J Thromb Haemost. 2007 Mar;5(3):490-6. doi: 10.1111/j.1538-7836.2007.02387.x. J Thromb Haemost. 2007. PMID: 17319904 Clinical Trial.
-
Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects.Int J Immunopathol Pharmacol. 2013 Apr-Jun;26(2):403-17. doi: 10.1177/039463201302600213. Int J Immunopathol Pharmacol. 2013. PMID: 23755755 Clinical Trial.
-
Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.Clin Ther. 2011 Dec;33(12):1883-93. doi: 10.1016/j.clinthera.2011.10.009. Epub 2011 Nov 10. Clin Ther. 2011. PMID: 22078153 Clinical Trial.
-
Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.Semin Thromb Hemost. 1997;23(4):349-56. doi: 10.1055/s-2007-996108. Semin Thromb Hemost. 1997. PMID: 9263351 Review.
-
Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract.Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):e1-e13. doi: 10.1016/j.bpg.2012.10.001. Best Pract Res Clin Gastroenterol. 2012. PMID: 23199511 Review.
Cited by
-
A narrative review of the cardiovascular risks associated with concomitant aspirin and NSAID use.J Thromb Thrombolysis. 2019 Jan;47(1):16-30. doi: 10.1007/s11239-018-1764-5. J Thromb Thrombolysis. 2019. PMID: 30406348 Review.
-
Clinical Pharmacology and Cardiovascular Safety of Naproxen.Am J Cardiovasc Drugs. 2017 Apr;17(2):97-107. doi: 10.1007/s40256-016-0200-5. Am J Cardiovasc Drugs. 2017. PMID: 27826802 Free PMC article. Review.
-
Thromboxane inhibition during concurrent therapy with low-dose aspirin and over-the-counter naproxen sodium.J Thromb Thrombolysis. 2018 Jan;45(1):18-26. doi: 10.1007/s11239-017-1593-y. J Thromb Thrombolysis. 2018. PMID: 29198079 Clinical Trial.